Cargando…

Cost-Effectiveness of Lorlatinib as a First-Line Therapy for Untreated Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

INTRODUCTION: Recently, a phase III CROWN trial compared the efficacy of two anaplastic lymphoma kinase (ALK) inhibitors and demonstrated that lorlatinib displayed clinical improvement over crizotinib for advanced non-small cell lung cancer (NSCLC) patients. Therefore, the aim of this study was to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203315/ https://www.ncbi.nlm.nih.gov/pubmed/34136409 http://dx.doi.org/10.3389/fonc.2021.684073

Ejemplares similares

Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure
por: Li, SiNi, et al.
Publicado: (2021)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
por: Li, SiNi, et al.
Publicado: (2021)

Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies
por: Li, SiNi, et al.
Publicado: (2021)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Lymphomatous Meningitis From Anaplastic Lymphoma Kinase+ Anaplastic Large T-Cell Lymphoma Treated With Lorlatinib: A Case Report
por: Mellacheruvu, Smitha, et al.
Publicado: (2022)

Uterine Leiomyosarcoma with FN1-Anaplastic Lymphoma Kinase Fusion Responsive to Alectinib and Lorlatinib
por: Testa, Stefano, et al.
Publicado: (2021)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
por: Xie, Jiao, et al.
Publicado: (2023)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020)

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden
por: Naik, Jaesh, et al.
Publicado: (2023)

Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
por: Li, Sini, et al.
Publicado: (2020)

4558 Investigating the functional consequences of anaplastic lymphoma kinase (ALK) mutations arising upon Lorlatinib treatment
por: Witek, Gabriela Maria, et al.
Publicado: (2020)

Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition
por: Sun, Steven, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece
por: Gourzoulidis, George, et al.
Publicado: (2022)

Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain
por: Presa, María, et al.
Publicado: (2023)

The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden
por: Nilsson, Fredrik O. L., et al.
Publicado: (2021)

Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2021)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

Correction to: Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
por: Hibma, Jennifer E., et al.
Publicado: (2022)

Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase
por: Liang, Shuai, et al.
Publicado: (2021)

Lorlatinib in previously treated anaplastic lymphoma kinase‐rearranged non–small cell lung cancer: Japanese subgroup analysis of a global study
por: Seto, Takashi, et al.
Publicado: (2020)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
por: Liu, Qiao, et al.
Publicado: (2020)

Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report
por: Wang, Huan, et al.
Publicado: (2023)

Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer
por: Chongqing, Tan, et al.
Publicado: (2021)

Primary gastric anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma
por: Tian, Chen, et al.
Publicado: (2016)

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report
por: Kashizaki, Fumihiro, et al.
Publicado: (2022)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA
por: Zeng, Xiaohui, et al.
Publicado: (2019)

A primary retroperitoneal anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor thrombosis
por: Li, Jisong, et al.
Publicado: (2018)

Comparative efficacy of various CHIs combined with western medicine for non-small cell lung cancer: A bayesian network meta-analysis of randomized controlled trials
por: Peng, Ciyan, et al.
Publicado: (2022)

Leukemic manifestation of anaplastic lymphoma kinase-negative-type anaplastic large-cell lymphoma
por: Kim, Jae Wook, et al.
Publicado: (2012)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase in Cutaneous Malignancies
por: Cao, Severine, et al.
Publicado: (2017)

Targeting anaplastic lymphoma kinase in neuroblastoma
por: Umapathy, Ganesh, et al.
Publicado: (2019)

Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
por: Loong, Herbert H., et al.
Publicado: (2020)

Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Peng, Ye, et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma
por: Ramteke, Prashant, et al.
Publicado: (2018)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

Anaplastic lymphoma kinase–positive anaplastic large cell lymphoma presenting as diffuse pulmonary infiltrates
por: Sato, Shuku, et al.
Publicado: (2020)

Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
por: Pokorna, Petra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_52mth0f7f0nbem29qpcfcnk13c